Portfolio companies news

11 September 2015

Briggs Morrison, CEO, Syndax Pharmaceuticals To Open ACRES Inaugural SYNERGY Event

Dr. Briggs Morrison, one of the world’s leading figures in drug development and immediate past Chairman of the Board of TransCelerate, an industry organization charged with improving the clinical trials process, will deliver the opening keynote address launching the Alliance for Clinical Research Excellence and Safety (ACRES) inaugural SYNERGY event to be held in Boston, October 1-2, 2015.

09 September 2015

Marinus Pharmaceuticals Announces Positive End-of-Phase 2 Meeting With FDA for Ganaxolone in Focal Onset Seizures

Marinus Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, announced today the successful completion of an End-of-Phase 2 meeting with the Food and Drug Administration (FDA). The objective of the meeting was to obtain FDA feedback on the nonclinical and clinical programs to support registration of ganaxolone for the adjunctive treatment of focal onset seizures in adults.

08 September 2015

Neothetics Announces Last Patient Enrolled in LIPO-202 Pivotal Phase 3 Clinical Trials for Reduction of Subcutaneous Abdominal Fat

Neothetics, Inc. (NASDAQ:NEOT), a clinical-stage specialty pharmaceutical company developing therapeutics for the aesthetic market, today announced completion of enrollment for its two pivotal U.S. Phase 3 trials titled AbCONTOUR1 and AbCONTOUR2. The trials are evaluating LIPO-202 for the reduction of central abdominal bulging due to subcutaneous fat in non-obese subjects. The Company expects to report top-line data by year-end.

02 September 2015

Epic Sciences to Present at World CDx Boston 2015

Epic Sciences, Inc. ("Epic Sciences"), announced today that Murali Prahalad, Ph.D., president and CEO, is scheduled to present at the World CDx Boston 2015, taking place at the Hilton Boston Logan Airport, September 8 – 11, 2015.

01 September 2015

Michael Meyers, M.D., Ph.D., Joins Syndax Pharmaceuticals As SVP And Chief Development Officer

Syndax Pharmaceuticals, Inc., a clinical stage biopharmaceutical company focused on developing entinostat as a combination therapy in multiple cancer indications, announced today the hiring of industry veteran Michael Meyers, M.D., Ph.D. to the position of Senior Vice President and Chief Development Officer. Dr. Meyers, who will report to Briggs Morrison, M.D., Chief Executive Officer of Syndax, will become a member of the senior management team, and be responsible for all aspects of clinical development of entinostat, Syndax's oral, small molecule that has direct effects on both cancer cells and immune regulatory cells, potentially enhancing anti-tumor immune responses.

27 August 2015

EPIC's Daniel Houston to Speak on Insurance and Risk Management Issues for Cyber, Technology, Media and Privacy at CFO Risk Management Summit

Cyber threats are one of the most significant risks businesses and individuals face today, says EPIC Insurance Brokers and Consultants. High profile breaches in the past few years have highlighted the substantial impact and significant costs associated with these attacks. And the breaches we hear about are just the tip of the iceberg, since information about an attack may not be revealed to the public if no personal data is stolen.

26 August 2015

Epic Sciences Appoints Dave Henderson as Chief Information Officer

Epic Sciences, Inc. (“Epic Sciences”), announced today the appointment of Dave Henderson as Epic Sciences’ chief information officer (CIO). Mr. Henderson has more than 20 years of experience in information technologies at companies including Sequenom, Inc., CBS Corporation, and Paramount Pictures Corporation. 

24 August 2015

Syndax Enters Clinical Trial Collaboration in Cancer Immunotherapy Combining Entinostat and Atezolizumab

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on developing entinostat as a combination therapy in multiple cancer indications, announced today that it has entered into a clinical collaboration with Genentech, a member of the Roche Group, to evaluate the safety, tolerability and preliminary efficacy of Syndax's entinostat, an oral small molecule that targets immune regulatory cells (myeloid-derived suppressor cells (MDSCs) and regulatory T cells (Tregs)), in combination with Genentech's atezolizumab (MPDL3280A), a fully humanized monoclonal antibody targeting protein programmed cell death ligand 1 (PD-L1), in patients with triple-negative breast cancer.

24 August 2015

Syndax Raises $80 Million In Series C Financing

Syndax Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing entinostat as a combination therapy in multiple cancer indications, announced today that it has completed an $80 millionSeries C financing. The financing was led by Fidelity Management & Research Company and Delos Capital Fund LP with participation from EcoR1 Capital, OrbiMed, Jennison Associates (on behalf of certain clients), Tavistock Life Sciences, Arrowpoint Partners, Cormorant Asset Management, BioMed Ventures and undisclosed top-tier mutual funds, as well as existing investors Domain Associates, MPM Capital, RusnanoMedInvest (RMI) and Forward Ventures.

18 August 2015

Epic Sciences' Dr. Dena Marrinucci Is Recognized as an Honoree of MIT Technology Review's Annual INNOVATORS UNDER 35 List

Today, MIT Technology Review revealed its annual list of Innovators Under 35. For over a decade, the global media company has recognized a list of exceptionally talented technologists whose work has great potential to transform the world. For her work in the field of biotechnology and medicine, Epic Sciences' Dena Marrinucci, Ph.D., has been recognized as an entrepreneur on the list for her groundbreaking work in developing and advancing a new technology to unlock the promise of using a simple blood test, called a liquid biopsy, to manage cancer treatments.